Sobi adds rare lymphoma drug with $580m Innate tie-up
Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
Quartet of biotechs join Nasdaq after stellar IPOs
Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
TransThera's resistant biliary cancer drug cleared in China
TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
Google defectors set up AI-based scientific method company
Four top AI figures at Google have left to form their own startup – Discovery Loop – dedicated to 'automating the experimental loop' in R&D.
Third time lucky for Replimune as FDA OKs melanoma drug
At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
Oncology
Patients
R&D
Partner Content
Inizio Launches Connected Insights to Transform Global Medic...
Expanded APAC expertise, enhanced global infrastructure, and AI-enabled innovation to help life sciences organizations
9th Lab Asset & Facility Management Summit
Enabling Leaner, Smarter & More Resilient R&D Labs
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.
Register Now for AAPS PharmSci 360!
Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.
16th World Clinical Biomarkers & CDx Summit
The industry's flagship drug-CDx forum widening global precision medicine access.